Ulocuplumab

Drug Profile

Ulocuplumab

Alternative Names: BMS-936564; MDX-1338

Latest Information Update: 07 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Medarex
  • Developer Bristol-Myers Squibb; Medarex
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Solid tumours
  • No development reported Acute lymphoblastic leukaemia; B cell lymphoma; B cell prolymphocytic leukaemia; Multiple myeloma

Most Recent Events

  • 29 Jun 2017 Bristol-Myers Squibb and Dana-Farber Cancer Institute plan a phase I/II trial in Waldenstrom's macroglobulinaemia (Combination therapy, Second-line therapy or greater) (IV) (NCT03225716)
  • 09 Mar 2017 Bristol-Myers Squibb terminates a phase I/II trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA, Finland due to lack of efficacy in the short term acute phase (NCT02472977)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top